Literature DB >> 15827792

Multicenter analysis of clinicopathologic features of intraductal papillary mucinous tumor of the pancreas: is it possible to predict the malignancy before surgery?

Jin-Young Jang1, Sun-Whe Kim, Young Joon Ahn, Yoo-Seok Yoon, Min Gew Choi, Kuhn Uk Lee, Joon Koo Han, Woo Ho Kim, Young Joo Lee, Song Chul Kim, Duck Jong Han, Yong Il Kim, Seong Ho Choi, Baik Hwan Cho, Hee Chul Yu, Dong Sup Yoon, Woo Jung Lee, Kyung Bum Lee, Young Chul Kim, Kwang Soo Lee, Myung-Wook Kim, Hong Jin Kim, Hyun Jong Kim, Yong-Hyun Park.   

Abstract

BACKGROUND: Despite recently increasing numbers of reports on intraductal papillary mucinous tumors (IPMTs), difficulties still remain in terms of diagnosis, treatment, and prognosis. The purpose of this multicenter study was to evaluate the clinicopathologic features of IPMT in Korea and to suggest predictive criteria for malignancy in IPMT.
METHODS: We retrospectively reviewed the clinicopathologic data of 208 patients who underwent operations for IPMT between 1993 and 2002 at 28 institutes in Korea.
RESULTS: Of the 208 patients (mean age, 61 years), 147 were men and 61 were women. A total of 124 patients underwent pancreatoduodenectomy, 42 underwent distal pancreatectomy, 17 underwent total pancreatectomy, and 25 underwent limited pancreatic resection. There were 128 benign cases (adenoma, n = 62; borderline, n = 66) and 80 malignant cases (noninvasive, n = 29; invasive, n = 51). A significant difference in 5-year survival was observed between the benign and malignant groups (92.6% vs. 65.3%; P = .006). Of the six factors (age, location, duct dilatation, mural nodule, main duct type, and tumor size) that showed statistical differences by univariate analysis between the benign and malignant groups, three were significant by multivariate analysis--namely, mural nodule (P = .009), tumor size (P = .023), and a dilated duct size (P = .010).
CONCLUSIONS: A significant proportion of IPMTs are malignant, although the overall prognosis of IPMT is superior to that of ordinary pancreatic cancer. Radical surgery is recommended for IPMT with the predictors of malignancy: mural nodule, tumor size (> or =30 mm), and dilated duct size (> or =12 mm).

Entities:  

Mesh:

Year:  2005        PMID: 15827792     DOI: 10.1245/ASO.2005.02.030

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  35 in total

1.  Predictive factors associated with malignancy of intraductal papillary mucinous pancreatic neoplasms.

Authors:  Jin Hee Lee; Kyu Taek Lee; Jongwook Park; Sun Youn Bae; Kwang Hyuck Lee; Jong Kyun Lee; Kee-Taek Jang; Jin Seok Heo; Seong Ho Choi; Dong Wook Choi; Jong Chul Rhee
Journal:  World J Gastroenterol       Date:  2010-11-14       Impact factor: 5.742

2.  Clinicopathologic analysis of surgically proven intraductal papillary mucinous neoplasms of the pancreas in SNUH: a 15-year experience at a single academic institution.

Authors:  Dae Wook Hwang; Jin-Young Jang; Seung Eun Lee; Chang-Sup Lim; Kuhn Uk Lee; Sun-Whe Kim
Journal:  Langenbecks Arch Surg       Date:  2010-07-18       Impact factor: 3.445

Review 3.  IPMN: surgical treatment.

Authors:  Reto M Käppeli; Sascha A Müller; Bianka Hummel; Christina Kruse; Philip Müller; Jürgen Fornaro; Alexander Wilhelm; Marcel Zadnikar; Bruno M Schmied; Ignazio Tarantino
Journal:  Langenbecks Arch Surg       Date:  2013-09-03       Impact factor: 3.445

Review 4.  [Intraductal papillary mucinous neoplasia: which findings support observation?].

Authors:  J Mayerle; M Kraft; P Menges; P Simon; J Ringel; L I Partecke; C D Heidecke; M M Lerch
Journal:  Chirurg       Date:  2012-02       Impact factor: 0.955

Review 5.  Intraductal papillary mucinous neoplasms of the pancreas: making a disposition using the natural history.

Authors:  L William Traverso; Toshiyuki Moriya; Yasushi Hashimoto
Journal:  Curr Gastroenterol Rep       Date:  2012-04

6.  Dynamic computed tomography findings of malignant intraductal papillary mucinous tumor compared with invasive ductal adenocarcinoma.

Authors:  Toshiro Ozaki; Takeshi Kamura; Yoichi Ajioka; Yoshio Shirai; Isao Kurosaki; Satoshi Yamamoto; Keisuke Sasai
Journal:  Radiat Med       Date:  2007-11-26

Review 7.  Total pancreatectomy: indications, operative technique, and postoperative sequelae.

Authors:  David G Heidt; Charles Burant; Diane M Simeone
Journal:  J Gastrointest Surg       Date:  2007-02       Impact factor: 3.452

8.  Pathologic Evaluation and Reporting of Intraductal Papillary Mucinous Neoplasms of the Pancreas and Other Tumoral Intraepithelial Neoplasms of Pancreatobiliary Tract: Recommendations of Verona Consensus Meeting.

Authors:  Volkan Adsay; Mari Mino-Kenudson; Toru Furukawa; Olca Basturk; Giuseppe Zamboni; Giovanni Marchegiani; Claudio Bassi; Roberto Salvia; Giuseppe Malleo; Salvatore Paiella; Christopher L Wolfgang; Hanno Matthaei; G Johan Offerhaus; Mustapha Adham; Marco J Bruno; Michelle D Reid; Alyssa Krasinskas; Günter Klöppel; Nobuyuki Ohike; Takuma Tajiri; Kee-Taek Jang; Juan Carlos Roa; Peter Allen; Carlos Fernández-del Castillo; Jin-Young Jang; David S Klimstra; Ralph H Hruban
Journal:  Ann Surg       Date:  2016-01       Impact factor: 12.969

9.  Pancreatic and extrapancreatic lesions in patients with intraductal papillary mucinous neoplasms of the pancreas: a single-centre experience.

Authors:  L Calculli; R Pezzilli; C Brindisi; R Morabito; R Casadei; M Zompatori
Journal:  Radiol Med       Date:  2010-01-15       Impact factor: 3.469

Review 10.  Management of mucin-producing cystic neoplasms of the pancreas.

Authors:  Stefan Fritz; Andrew L Warshaw; Sarah P Thayer
Journal:  Oncologist       Date:  2009-02-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.